HCV elimination metrics data through 2021 are featured in new interactive dashboard visualizations displaying trends of two key metrics – diagnosis and treatment/clearance rates. Dashboard users will be able to view these data by geographic area (e.g. region, county, NTA neighborhood) and by sex or age group using data from the Hepatitis Elimination and Epidemiology Dataset (HEED).
Hepatitis Elimination and Epidemiology Dataset (HEED)
HEED is an innovative system that improves HCV elimination monitoring in New York State (NYS) by integrating data from multiple sources to capture more complete data on HCV testing and treatment. HEED was developed utilizing laboratory test result data from the Electronic Clinical Laboratory Reporting System (ECLRS) and case surveillance data from the NYS Communicable Disease Electronic Surveillance System (CDESS) and MAVEN, which collect local health department data from across NYS and New York City, respectively.
HEED builds upon the current HCV reporting system and is designed to support HCV elimination efforts by accounting for individuals with a history of, or current, HCV infection, and treatment status.
HCV Elimination Metrics
To eliminate HCV, NYS has set the following targets based on World Health Organization goals to achieve HCV elimination worldwide by 2030: increase diagnoses to 90% of people living with HCV; increase treatment/clearance to 80% of people diagnosed with HCV; reduce new infections by 80%; reduce prevalence by 90%; and decrease liver-related deaths by 65%. To monitor progress on these targets, the dashboard now presents data for two key metrics: HCV diagnoses and HCV treatment/clearance.
While HCV diagnosis rates have declined among all New Yorkers, rates are almost twice as high among males (37.7 per 100,000) than females (19.5 per 100,000) in 2021 and the largest decreases in recent years have been among people aged 40-69.
The cumulative percentage of people diagnosed with HCV from 2010 to 2021 who cleared their infection either through treatment or spontaneously has increased from 19.8% in 2015 to 51.7% in 2021.
Treatment/clearance varies by region, with the highest proportion of people with diagnosed HCV treated/cleared in the Lower Hudson Region (56.6%) and the lowest in Western NY (43.4%). Treatment/clearance also varies by age group, with the highest proportion of those treated/cleared among people aged 40-69.
By making state and local HCV data available to all stakeholders, the HCV Dashboard can help inform decision-making, monitor trends, and identify gaps in the effort to eliminate HCV in NYS. Stay up to date on the latest publicly available data and future enhancements to the HCV Dashboard by signing up to our mailing list and following us on social media.
 Treatment/clearance is defined as the cumulative percent of individuals diagnosed with HCV since 2010 with evidence of treatment for, or clearance of, hepatitis C infection, per year. Negative HCV RNA results became reportable in NYC in 2014 and statewide in 2016, allowing the identification of people who have cleared their infection, either following treatment, or spontaneously without treatment. Patients who cleared their infection prior to when negative HCV RNA results were reportable may not be identified as such, resulting in an underestimate of this metric.